immunosuppressive treatment

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
BACKGROUND: Anti-drug antibodies (ADAb) frequently form early in the treatment course of infliximab and other tumour necrosis factor …